Former US House speaker to promote legalizing marijuana

Former US House speaker to promote legalizing marijuana

https://s.yimg.com/ny/api/res/1.2/_g...613.png.cf.jpg
DAN SEWELL
,Associated Press•April 11, 2018

CINCINNATI (AP) — Former U.S. House Speaker John Boehner said Wednesday he has had a change of heart on marijuana and will promote its nationwide legalization as a way to help veterans and the nation's deadly opioid crisis.

The Ohio Republican, an avid cigarette smoker, has joined the advisory board of Acreage Holdings , a multistate cannabis company. The company also announced that former Massachusetts Gov. William Weld has joined its advisory board.
Weld, a Republican as governor, ran in the 2016 presidential election on the Libertarian Party ticket that was headed by legal-pot advocate Gary Johnson.

Boehner said in a statement his position "has evolved" from opposing to supporting legalization of marijuana.

"I decided to get involved because of the struggles of our country's veterans and the opioid epidemic, after learning how descheduling the drug can potentially help with both crises," said Boehner, now 68.

He said he wants to see federally funded research done and to allow the Department of Veterans Affairs to offer marijuana as a possible treatment option for such conditions as chronic pain and post-traumatic stress disorder.

Boehner also said the move would curtail federal-state conflict on marijuana policies.

While marijuana is illegal at the federal level, most states have legalized pot in some form.

President Donald Trump's administration in January lifted a Barack Obama-era policy that discouraged federal authorities from cracking down on the pot trade in states where the drug is legal.

New York-based Acreage, which has cannabis operations in 11 states, said Boehner and Weld will serve on its board of directors when that is formed. Boehner had an earlier stint on a tobacco's company's board.

Paul Ryan, Boehner's successor when he resigned as speaker in 2015, had talked about the work of getting the smell of cigarette smoke out of the speaker's office after Boehner's departure.

https://www.yahoo.com/news/former-us-house-speaker-promote-legalizing-marijuana-164553769.html

Boehner could care less about our veterans (IMO). This is probably all about the greenback for him. Of course I guess there is an outside chance he gave up his heavy drinking and is now toking on the laughing grass.

Quote:

---

He said he wants to see federally funded research done and to allow the Department of Veterans Affairs to offer marijuana as a possible treatment option for such conditions as chronic pain and post-traumatic stress disorder.

---

Quote:

---

New York-based Acreage, which has cannabis operations in 11 states, said Boehner and Weld will serve on its board of directors when that is formed. Boehner had an earlier stint on a tobacco's company's board.

---

$$$$$$$$$$ - on the board, guess stock for sure too. The latest big money maker "weed". They could actually use the cannabanoid part w/o the thc and no smoke method but might not be as popular.

Good! But just get the damn feds out of it. Legalize and let the states handle their own marijuana businesses. They'll do a good job.

Quote:

---

Originally Posted by Judy

Good! But just get the damn feds out of it. Legalize and let the states handle their own marijuana businesses. They'll do a good job.

---

Sort of like California is doing on illegal immigration?

Top 4 Marijuana Stocks to Watch

By Kevin Johnston | Updated April 2, 2018 — 7:19 PM EDThttps://i.investopedia.com/public/im...k-share-14.png SHARE

ADD TO WATCHLISTABBV
AbbVie Inc
93.64
+0.02%



SMG
The Scotts Miracle-Gro Co
82.15
-1.55%


INSY
Insys Therapeutics Inc
6.22
+1.47%


CRON
Cronos Group Inc
6.36
-0.16%

View Watchlist

California joined the list of states to legalize recreational marijuana use at the start of 2018, and the markets are showing some enthusiasm for stocks related to the controversial plant. But some of that cheer was muted when reports of stricter federal law enforcement on marijuana came to light. Attorney General Jeff Sessions is set to rescind an Obama-era rule of federal non-interference in state marijuana law enforcement.

Currently, nine states and the District of Columbia have legalized recreational marijuana, while the substance is legal for medical purposes in 29 states. However, marijuana remains illegal at the federal level.

The rush to get in on the marijuana craze has created hundreds of startups, but the odds are that many of these will fail. With a federal clampdown, the probability is higher that many marijuana-based startups won't survive. The winners in the industry so far are established companies that are adding marijuana to their focus.
(See also: Want to Make Money in Marijuana? Read This First.)

We have selected four marijuana stocks that have the potential to make significant gains.

These stocks were chosen based on their array of marijuana-related products. These products are either in use or awaiting approval by the Food and Drug Administration (FDA). All figures are current as of April 2, 2018.

[Just like any stocks, marijuana stocks need to be properly analyzed before deciding if they are a smart investment. If you're looking to learn how to use fundamental analysis to make investment decisions, Investopedia Academy offers a Find Great Value Stocks course that could be right for you. ]

1. AbbVie Inc. (ABBVABBV
AbbVie Inc
93.64
+0.02%

)

AbbVie is a pharmaceutical company that is ahead of the pack because it has a cannabis-based drug on the market. The FDA approved Marinol, which helps alleviate nausea or vomiting for chemotherapy patients. The drug also helps AIDS patients who have lost their desire to eat. It is important to note that Marinol is not AbbVie's flagship drug. In fact, it is not even the company's biggest seller.

AbbVie has reported increasing revenues in the past four years. In addition, its operating income has been increasing steadily. The company is benefiting from a host of useful drugs, including Marinol. Therefore, AbbVie is a way to play the marijuana trend without incurring 100% exposure to the plant. One risk of owning AbbVie is that it concentrates almost exclusively on U.S. markets, whereas most pharmaceutical companies market internationally. If the domestic market falters, the stock could see a drop in value. For investors, this risk is offset by the dividend, which is currently 3.91%. (For more, see: How AbbVie Makes Its Money.)

• Average Volume: 7,176,521
• Market Cap: $145.119 billion
• P/E Ratio (TTM): 27.72
• EPS (TTM): $3.30
• Dividend and Yield: $3.84 (3.91%)

2. The Scotts Miracle-Gro Company (SMGSMG
The Scotts Miracle-Gro Co
82.15
-1.55%

)

An interesting way to play the marijuana boom is Scotts Miracle-Gro. Known for its lawn and garden-care lines, the company is developing products for cannabis growers and also several pesticides for use on marijuana plants.

The stock entered a sideways pattern in December 2016 and then dropped sharply in June 2017. Scotts shares moved up again into year end, touching all-time highs of over $109 in January 2018. However, Scotts Miracle-Gro shares plunged 15% on Jan. 30 as the markets reacted to a disappointing earnings report, settling at around $90 before continuing their decline in March toward current levels around $83. In a press release, the company's CEO attributed the weak performance in pot-related business to "the slower-than-expected pace of regulatory changes in California." For investors who are bullish on marijuana and Scotts' more traditional core businesses, the recent pullback could represent a buying opportunity.
(See also: Scotts Miracle-Gro Seeks High Profits in Marijuana.)

• Average Volume: 650,168
• Market Cap: $4.741 billion
• P/E Ratio (TTM): 18.92
• EPS (TTM): $4.40
• Dividend and Yield: $2.12 (2.49%)

3. INSYS Therapeutics, Inc. (INSYINSY
Insys Therapeutics Inc
6.22
+1.47%


)

Although this company markets many non-cannabis drugs, it is in the process of developing a synthetic cannabis drug to treat childhood epilepsy. INSYS is working on a spray technology to deliver pharmaceutical cannabinoids.

INSYS has had flat revenues for the past three years, but its operating income showed a sharp drop at the end of 2016 as the company spent more on research. Gross profit is higher than it was three years ago. Throughout October 2017, the stock fell sharply below prior support levels of $9 per share and then began moving sideways at just above $5 per share. The stock saw a sharp breakout in December and into the New Year, more than doubling in value to over $13, but it has recently pulled back to just under $6. There has been more volatility than a prudent investor would usually want to see, but given that this is a biotech stock, the action is acceptable.
(For more, see: INSYS Stock Breaks Out, but How Long Will Rally Last?)

• Average Volume: 1,426,372
• Market Cap: $439.636 million
• P/E Ratio (TTM): N/A
• EPS (TTM): -$3.16
• Dividend and Yield: N/A (N/A)

4. Cronos Group Inc. (CRONCRON
Cronos Group Inc
6.36
-0.16%


)

Toronto-based Cronos Group became the first cannabis "plant-touching" company to be listed on the Nasdaq in February 2018. The company has medical marijuana production and distribution operations across many different countries like Israel, Canada, Germany and Australia.

The move to Nasdaq from the OTC market, where Cronos shares traded as American Depository Receipts (ADRs), saw the stock surge more than 20%. However, the challenge for Cronos is that, unlike other geographies in which it operates, marijuana and cannabis continue to be illegal in the United States at the federal level. For a company that does not have active operations in the country and operates in a sector that could see significant tightening of regulation, that might just be a tough spot to be in.
(For more, see: Cronos Group Will Be Nasdaq's First Pot Stock.)

• Average Volume: 4,239,321
• Market Cap: $1.061 billion
• P/E Ratio (TTM): 781.25
• EPS (TTM): $0.01
• Dividend and Yield: N/A (N/A)

Read more: Top 4 Marijuana Stocks to Watch | Investopedia

https://www.investopedia.com/investi...#ixzz5CPpHlb5L

Follow us: Investopedia on Facebook

Illegal immigration is determined by federal law. I'm saying legalize weed at the federal level which means states will set their own laws and regulations on marijuana and run their own programs. States who don't want it, ban it. States who do want it, regulate and tax it.

But if states were allowed by the federal government to have their own state laws on illegal immigration that either conformed with or exceeded federal regulations, they would do a much better job of enforcing US immigration law than the feds have demonstrated until President Trump came along, and it would be much cheaper. Then the feds could focus on the borders and assisting the states. States that refuse to enforce immigration laws in their state would be handled by the feds and the cost would be deducted from their federal highway, education and Medicaid funding.

Quote:

---

Originally Posted by JohnDoe2

Top 4 Marijuana Stocks to Watch

By Kevin Johnston | Updated April 2, 2018 — 7:19 PM EDThttps://i.investopedia.com/public/im...k-share-14.png SHARE

ADD TO WATCHLISTABBV
AbbVie Inc
93.64
+0.02%



SMG
The Scotts Miracle-Gro Co
82.15
-1.55%


INSY
Insys Therapeutics Inc
6.22
+1.47%


CRON
Cronos Group Inc
6.36
-0.16%

View Watchlist

California joined the list of states to legalize recreational marijuana use at the start of 2018, and the markets are showing some enthusiasm for stocks related to the controversial plant. But some of that cheer was muted when reports of stricter federal law enforcement on marijuana came to light. Attorney General Jeff Sessions is set to rescind an Obama-era rule of federal non-interference in state marijuana law enforcement.

Currently, nine states and the District of Columbia have legalized recreational marijuana, while the substance is legal for medical purposes in 29 states. However, marijuana remains illegal at the federal level.

The rush to get in on the marijuana craze has created hundreds of startups, but the odds are that many of these will fail. With a federal clampdown, the probability is higher that many marijuana-based startups won't survive. The winners in the industry so far are established companies that are adding marijuana to their focus.
(See also: Want to Make Money in Marijuana? Read This First.)

We have selected four marijuana stocks that have the potential to make significant gains.

These stocks were chosen based on their array of marijuana-related products. These products are either in use or awaiting approval by the Food and Drug Administration (FDA). All figures are current as of April 2, 2018.

[Just like any stocks, marijuana stocks need to be properly analyzed before deciding if they are a smart investment. If you're looking to learn how to use fundamental analysis to make investment decisions, Investopedia Academy offers a Find Great Value Stocks course that could be right for you. ]

1. AbbVie Inc. (ABBVABBV
AbbVie Inc
93.64
+0.02%

)

AbbVie is a pharmaceutical company that is ahead of the pack because it has a cannabis-based drug on the market. The FDA approved Marinol, which helps alleviate nausea or vomiting for chemotherapy patients. The drug also helps AIDS patients who have lost their desire to eat. It is important to note that Marinol is not AbbVie's flagship drug. In fact, it is not even the company's biggest seller.

AbbVie has reported increasing revenues in the past four years. In addition, its operating income has been increasing steadily. The company is benefiting from a host of useful drugs, including Marinol. Therefore, AbbVie is a way to play the marijuana trend without incurring 100% exposure to the plant. One risk of owning AbbVie is that it concentrates almost exclusively on U.S. markets, whereas most pharmaceutical companies market internationally. If the domestic market falters, the stock could see a drop in value. For investors, this risk is offset by the dividend, which is currently 3.91%. (For more, see: How AbbVie Makes Its Money.)

• Average Volume: 7,176,521
• Market Cap: $145.119 billion
• P/E Ratio (TTM): 27.72
• EPS (TTM): $3.30
• Dividend and Yield: $3.84 (3.91%)

2. The Scotts Miracle-Gro Company (SMGSMG
The Scotts Miracle-Gro Co
82.15
-1.55%

)

An interesting way to play the marijuana boom is Scotts Miracle-Gro. Known for its lawn and garden-care lines, the company is developing products for cannabis growers and also several pesticides for use on marijuana plants.

The stock entered a sideways pattern in December 2016 and then dropped sharply in June 2017. Scotts shares moved up again into year end, touching all-time highs of over $109 in January 2018. However, Scotts Miracle-Gro shares plunged 15% on Jan. 30 as the markets reacted to a disappointing earnings report, settling at around $90 before continuing their decline in March toward current levels around $83. In a press release, the company's CEO attributed the weak performance in pot-related business to "the slower-than-expected pace of regulatory changes in California." For investors who are bullish on marijuana and Scotts' more traditional core businesses, the recent pullback could represent a buying opportunity.
(See also: Scotts Miracle-Gro Seeks High Profits in Marijuana.)

• Average Volume: 650,168
• Market Cap: $4.741 billion
• P/E Ratio (TTM): 18.92
• EPS (TTM): $4.40
• Dividend and Yield: $2.12 (2.49%)

3. INSYS Therapeutics, Inc. (INSYINSY
Insys Therapeutics Inc
6.22
+1.47%


)

Although this company markets many non-cannabis drugs, it is in the process of developing a synthetic cannabis drug to treat childhood epilepsy. INSYS is working on a spray technology to deliver pharmaceutical cannabinoids.

INSYS has had flat revenues for the past three years, but its operating income showed a sharp drop at the end of 2016 as the company spent more on research. Gross profit is higher than it was three years ago. Throughout October 2017, the stock fell sharply below prior support levels of $9 per share and then began moving sideways at just above $5 per share. The stock saw a sharp breakout in December and into the New Year, more than doubling in value to over $13, but it has recently pulled back to just under $6. There has been more volatility than a prudent investor would usually want to see, but given that this is a biotech stock, the action is acceptable.
(For more, see: INSYS Stock Breaks Out, but How Long Will Rally Last?)

• Average Volume: 1,426,372
• Market Cap: $439.636 million
• P/E Ratio (TTM): N/A
• EPS (TTM): -$3.16
• Dividend and Yield: N/A (N/A)

4. Cronos Group Inc. (CRONCRON
Cronos Group Inc
6.36
-0.16%


)

Toronto-based Cronos Group became the first cannabis "plant-touching" company to be listed on the Nasdaq in February 2018. The company has medical marijuana production and distribution operations across many different countries like Israel, Canada, Germany and Australia.

The move to Nasdaq from the OTC market, where Cronos shares traded as American Depository Receipts (ADRs), saw the stock surge more than 20%. However, the challenge for Cronos is that, unlike other geographies in which it operates, marijuana and cannabis continue to be illegal in the United States at the federal level. For a company that does not have active operations in the country and operates in a sector that could see significant tightening of regulation, that might just be a tough spot to be in.
(For more, see: Cronos Group Will Be Nasdaq's First Pot Stock.)

• Average Volume: 4,239,321
• Market Cap: $1.061 billion
• P/E Ratio (TTM): 781.25
• EPS (TTM): $0.01
• Dividend and Yield: N/A (N/A)

Read more: Top 4 Marijuana Stocks to Watch | Investopedia

https://www.investopedia.com/investi...#ixzz5CPpHlb5L

Follow us: Investopedia on Facebook

---

Cool!! They're on the stock market. Wow!!

Nasdaq to Get First Pot Listing - Bloomberg
https://www.bloomberg.com/.../nasdaq-to-get-first-pot-listing-as-cronos-group-joins-e...
Feb 26, 2018 - The Nasdaq Stock Market will list its first cannabis shares on Tuesday, marking a key milestone for an industry that has been rejected by the Trump administration. Cronos Group Inc., which already trades in Canada, will be the first marijuana company on a major U.S. exchange -- right alongside Nasdaq ...

Quote:

---

Originally Posted by JohnDoe2

Nasdaq to Get First Pot Listing - Bloomberg
https://www.bloomberg.com/.../nasdaq-to-get-first-pot-listing-as-cronos-group-joins-e...
Feb 26, 2018 - The Nasdaq Stock Market will list its first cannabis shares on Tuesday, marking a key milestone for an industry that has been rejected by the Trump administration. Cronos Group Inc., which already trades in Canada, will be the first marijuana company on a major U.S. exchange -- right alongside Nasdaq ...

---

Not exactly something to boast about in my opinion.

Acreage Holdings
https://www.acreageholdings.com/
Acreage Holdings is an investment company with an established footprint in the cannabis industry in the United States, operating in 11 states nationwide. With seed-to-dispensary operations, Acreage is moving towards the creation of a vertically integrated brand with stakes in cultivation, processing and dispensing of ...‎

About · ‎Team · ‎Careers · ‎Contact

https://static1.squarespace.com/stat...rketReport.png

High Street Capital is now Acreage Holdings
Mar 13, 2018

Source: Green Market Report, Debra Borchardt
New York-based High Street Capital has changed its name to Acreage Holdings and has pivoted from passive cannabis investing to a company that actively owns and manages medical marijuana facilities. The company plans on pursuing an initial public offering.
It’s one of the few multi-state cannabis companies that many have never heard of. It was founded in 2014 by Kevin Murphy and was one of the first platforms to invest systematically in the cannabis space.

Read More

John Boehner Gets into the Legal Weed Business

by Katie Herzog • Apr 11, 2018 at 10:52 am

https://www.redditstatic.com/spreddit5.gif

And the latest rich white dude to enter the legal weed market is...

https://pbs.twimg.com/profile_images...mhd_normal.jpgJohn Boehner
✔@SpeakerBoehner


I’m joining the board of #AcreageHoldings because my thinking on cannabis has evolved. I’m convinced de-scheduling the drug is needed so we can do research, help our veterans, and reverse the opioid epidemic ravaging our communities. @AcreageCannabis https://www.acreageholdings.com/news-release-board-of-advisors-appointment …

6:58 AM - Apr 11, 2018
https://pbs.twimg.com/card_img/98365...name=144x144_2


News Release: Board of Advisors Appointment

acreageholdings.com

• 
  23.6K
• 
  13.1K people are talking about this

Twitter Ads info and privacy


John Boehner, if you recall, is the former GOP House speaker who was opposed to cannabis legalization until five minutes ago, when he apparently realized that he could profit from it.

Boehner, who resigned from the House in 2015, will be joining the advisory board of New York-based Acreage Holdings (formerly known as High Street Capital Partners), a company that started out as an investment firm in the cannabis biz before pivoting, last year, into cultivating and selling weed itself. Acreage now has operations in 11 states, including in Oregon, where they run five dispensaries.

Boehner will be joined by former Massachusetts governor Bill Weld, who is also joining the Acreage board. In a joint statement, they said, "Over the past 20 years a growing number of states have experimented with their right to offer cannabis programs under the protection of the 10th amendment. During that period, those rights have lived somewhat in a state of conflict with federal policy. Also, during this period, the public perception of cannabis has dramatically shifted, with 94% of Americans currently in favor of some type of access, a shift driven by increased awareness of marijuana’s many medical applications."

Looking forward to next year, when newly retired Jeff Sessions announces he's joined the board of Uncle Ike's.

https://www.thestranger.com/slog/201...-weed-business


Just like the states legalizing marijuana, Boehner is grubbing for his own stake in the 'misery market' money! As former Speaker of the House he was a disgusting drunk. Now he's taking advantage of his former fame to become a disgusting money grubber.

Quote:

---

Boehner will be joined by former Massachusetts governor Bill Weld, who is also joining the Acreage board. In a joint statement, they said, "Over the past 20 years a growing number of states have experimented with their right to offer cannabis programs under the protection of the 10th amendment. During that period, those rights have lived somewhat in a state of conflict with federal policy. Also, during this period, the public perception of cannabis has dramatically shifted, with 94% of Americans currently in favor of some type of access, a shift driven by increased awareness of marijuana’s many medical applications."

---

It's the right thing to do.

Boehner Backs Righteous Buds, Pot Buds

April 11, 2018 Tea Party ConservativeUS News

https://joeforamerica.com/wp-content...ot-750x430.jpg
For Republican House Speaker John Boehner announced a surprising shift in focus after his thinking on the application of cannabis has “evolved.”

Now, Boehner will be using his years of experience in the legislative process to make it easier to conduct research on the efficacy of weed’s active ingredients for medical purposes. Aside from helping veteran, Boehner believes that research into the wacky tobaccy will help veterans and help to stem the tide of the opioid epidemic. And there’s a good chance he’s got the right idea.

https://joeforamerica.com/wp-content...t-1200x799.jpg

https://pbs.twimg.com/profile_images...mhd_normal.jpgJohn Boehner
✔@SpeakerBoehner


I’m joining the board of #AcreageHoldings because my thinking on cannabis has evolved. I’m convinced de-scheduling the drug is needed so we can do research, help our veterans, and reverse the opioid epidemic ravaging our communities. @AcreageCannabis https://www.acreageholdings.com/news-release-board-of-advisors-appointment …
6:58 AM - Apr 11, 2018
https://pbs.twimg.com/card_img/98365...name=144x144_2


News Release: Board of Advisors Appointment

acreageholdings.com

• 
  
• 13.1K people are talking about this

Twitter Ads info and privacy


John Boehner

Boehner, as a Republican from Ohio was the House Minority Leader from 2007-2011 after a brief stint as Majority Leader starting in 2006. Then, he moved on to be the Speaker of the House of Representatives from 2011 to 2015 before being succeeded by Paul Ryan.

Boehner grew up playing high school football, and was dishonorably discharged from the US Navy for a bad back after enlisting during the Vietnam War.

Acreage Holdings

As one of the country’s biggest cannabis companies, Acreage Holdings was founded in 2014 to pursue the cultivation, processing and dispensing of weed in America and currently has holdings in 11 states. According to their website:

“Our mission is to become the world’s leading cannabis company, bringing safe, affordable cannabis to everyone who needs it. With that in mind, we’re ready to build on the vertically integrated operations (cultivating, processing and dispensing) we’ve established in 11 states and be part of a transformative market potentially worth $40 billion, but worth so much more to the people who find hope and health through this amazing plant.”

Press Release on Boehner from Acreage

“While the Tenth Amendment has allowed much to occur at the state level, there are still many negative implications of the Federal policy to schedule cannabis as a Class 1 drug: most notably the lack of research, the ambiguity around financial services and the refusal of the VA to offer it as an alternative to the harmful opioids that are ravishing our communities.”

The Tenth Amendment

As mentioned above, states are empowered to make their own laws governing weed.

“The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.”

Class 1 Drug

A class 1 (or schedule 1) drug is defined by the DEA as drugs with “no currently accepted medical use and a high potential for abuse.” Examples of this class of drug are listed as:

• Heroin
• LSD
• Pot
• Ecstasy
• Peyote
• 
  

Acreage Holdings wants weed to be removed from this classification because they believe that more scientific testing must be permitted to be carried out to find value. Right now, experimenting on the uses of weed fall to other countries. For example, starting in July, weed will be legal for Canadians to purchase and use recreationally, and it will open up the market there for scientists looking to study the drug. But there is a difference: the Canadian government is admitting that it’s for recreation, not for medicine.

Is Medical Pot All That?

Recently, the Journal of the American Medical Association announced that there is only “moderate-quality evidence” that supports any benefits of medical weed, and only for a limited number of conditions. The report states that most weed studies are of “lesser quality” and are more likely to contain bias.

Welfare and Drug Testing for Work

This week, Donald Trump signed a new executive order asking several departments to return a report in the next 90 days asking for ways that they can address welfare abuse issues and shore up the work requirements for people receiving benefits. With the emergence of medical weed and loosened drug laws, this will likely be addressed when Trump authorizes an update on how welfare and SNAP benefits are allotted.

Last month we reported that with the passing of more laws to legalize weed, some companies have phased out drug testing. But other companies, ones that manufacture products or otherwise need to make sure they have an alert workforce because of the level of danger are having trouble filling thousands of positions because they say the opioid crisis means many applicants are turned down due to painkillers in their system.

http://ussanews.com/News1/2018/04/11/boehner-backs-righteous-buds-marijuana-buds/

Quote:

---

Boehner grew up playing high school football, and was dishonorably discharged from the US Navy for a bad back after enlisting during the Vietnam War.

---

Somebody has got their facts confused because you don't get "dishonorably discharged" from the military for a bad back. For a bad back you receive an administrative or medical discharge. Well, we always knew crybaby Boehner was spineless, now we know the rest of the story.

Quote:

---

Boehner attended Cincinnati's Moeller High School and was a linebacker on the school's football team, where he was coached by future Notre Dame coach Gerry Faust.[19] Graduating from Moeller in 1968, when United States involvement in the Vietnam War was at its peak, Boehner enlisted in the United States Navy but was honorably discharged after eight weeks because of a bad back.[20] He earned his B.A. in business administration from Xavier University in 1977, becoming the first person in his family to attend college, taking seven years as he held several jobs to pay for his education.[9]

---

https://en.wikipedia.org/wiki/John_Boehner

Quote:

---

Originally Posted by Judy

https://en.wikipedia.org/wiki/John_Boehner

---

Like I said, it would have been an administrative or medical discharge. Those are under honorable conditions. A bad back is not a reason for a dishonorable discharge. You didn't need to go to wikipedia to verify that. :lol:

Trump agrees to leave state-legal marijuana programs alone

Medical pot producer Aphria earns $12.9 million, boosted by sale of Liberty Health Sciences shares

Aphria’s stock rose 7.37 per cent to $12.24 on the Toronto Stock Exchange in Monday trading.

https://www.thestar.com/content/dam/...p.1086x674.jpg

Aphria reported quarterly revenues that more than doubled to $10.3 million, compared with a year ago, and an improvement in its all-in costs of sales of dried cannabis per gram to $1.56, down from $2.13 in the same quarter of 2017. (THE CANADIAN PRESS)

By The Canadian Press
Mon., April 16, 2018


Shares of licensed medical marijuana producer Aphria Inc. rose nearly nine per cent on Monday on better than expected quarterly results and after news of a changing political tone on cannabis south of the border.

Aphria reported a $12.9-million profit in its latest quarter, boosted by the sale of some of its shares in U.S. company Liberty Health Sciences.

The Leamington, Ont.-based producer’s stock rose 7.37 per cent to $12.24 on the Toronto Stock Exchange in trading Monday.

Read more:
Licensed marijuana producer Aphria signs deal to buy Nuuvera

Aphria buys Broken Coast Cannabis as the marijuana market consolidates further

Weed company Aphria sells part of stake in U.S. firm as it pulls from country

Aphria’s chief executive Vic Neufeld said Monday the company is “very excited” about political developments south of the border, where cannabis is illegal under U.S. federal law, including U.S. President Donald Trump’s commitment last week to support congressional efforts to protect states that have legalized cannabis.

Neufeld said Liberty Health Sciences, which has interests in states where pot is legal and in which Aphria has a 28-per-cent stake, has been “given a stamp of validation by key political leaders.”

“We are very excited that this has happened,” he told analysts discussing its latest quarterly results. “We were very confident it would ... Liberty was just ahead of the curve.”

Aphria moved to reduce its stake in Liberty earlier this year after Canada’s biggest exchange operator warned in October that U.S. federal law takes precedence over state laws, and cannabis firms with cross-border activities may face delisting. In January, U.S. Attorney General Jeff Sessions rescinded an Obama-era memo that suggested that the federal government would not intervene in states where cannabis is legal, and said he was leaving it to federal prosecutors in those states to decide how aggressively to enforce federal law.

Aphria sold 26.7 million Liberty shares at a price of $1.25 per share, representing all its shares in the company that are not subject to Canadian Securities Exchange escrow requirements and maintained a 28.1 per cent after the transaction.

But on Friday, Colorado Senator Cory Gardner said he received a commitment from Trump that the memo’s rescission would not impact Colorado’s legal marijuana industry.

While Neufeld viewed this as positive, he told analysts Monday he did not expect the TMX Group, which operates the Toronto Stock Exchange and the Venture exchange, to change its stance soon.

Aphria does not anticipate “enough advancement” between now and late July, when the licensed producer is due to reduce its stake in Liberty Health Sciences further to 20 per cent, said Neufeld.

“This is just another advancement of eventually getting to the position of where medical cannabis moves to Schedule 2,” he told analysts. “That journey is still a long way off.”

Meanwhile, Aphria reported quarterly revenues that more than doubled to $10.3 million, compared with a year ago, and an improvement in its all-in costs of sales of dried cannabis per gram to $1.56, down from $2.13 in the same quarter of 2017.

The company said the its latest quarterly profit amounted to eight cents per share for the quarter ended Feb. 28 compared with a profit of nearly $5 million or four cents per share a year ago when it had fewer shares outstanding.

https://www.thestar.com/business/201...es-shares.html

Former Mexico President Vicente Fox Joins High Times Board